Treatment with clinical EGFR-TKIs (erlotinib, gefitinib, and lapatinib) resulted in the accumulation of αvβ3 integrin-positive cells, thereby leading to resistance to the aforementioned EGFR-TKIs in NSCLC cell lines (A549, H1975, and Lewis) [128]. Here, EGFR is linked to non-small cell lung carcinoma.